The relationship between diabetes and pancreatic cancer

被引：191
作者：
Feng Wang
Margery Herrington
Jörgen Larsson
Johan Permert
机构：
[1] Surgery Department, Karolinska Institute, Huddinge University Hospital
[2] Department of Biology, Adams Stage College, Alamosa
来源：
Molecular Cancer | / 2卷 / 1期
关键词：
Pancreatic Cancer; Pancreatic Cancer Cell; Pancreatic Cancer Cell Line; Pancreatic Cancer Patient; Human Pancreatic Cancer Cell;
D O I：
10.1186/1476-4598-2-4
中图分类号：
学科分类号：
摘要：
About 80% of pancreatic cancer patients have glucose intolerance or frank diabetes. This observation has led to the following two hypotheses: i. pancreatic cancer causes the associated diabetes and ii. the conditions associated with diabetes promote the development of pancreatic cancer. Evidence supporting both hypotheses has been accumulated in previous studies. This article reviews these studies, especially those that have been conducted recently. -cr 2003 Wang et al; licensee BioMed Central Ltd.
引用
收藏
页数：5
相关论文
共 61 条
  • [1] Nix G.A., Schmitz P.I., Wilson J.H., van Blankenstein M., Groeneveld C.F., Hofwijk R., Carcinoma of the head of the pancreas. Therapeutic implications of endoscopic retrograde cholangiopancreatography findings, Gastroenterology, 87, pp. 37-43, (1984)
  • [2] Gullo L., Tomassetti P., Migliori M., Casadei R., Marrano D., Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis?, Pancreas, 22, pp. 210-213, (2001)
  • [3] Gudjonsson B., Cancer of the pancreas. 50 years of surgery, Cancer, 60, pp. 2284-2303, (1987)
  • [4] Permert J., Ihse I., Jorfeldt L., von Schenck H., Arnqvist H.J., Larsson J., Pancreatic cancer is associated with impaired glucose metabolism, Eur. J. Surg., 159, pp. 101-107, (1993)
  • [5] Schwarts S.S., Zeidler A., Moossa A.R., Kuku S.F., Rubenstein A.H., A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma, Dig. Dis., 23, pp. 1107-1114, (1978)
  • [6] Gullo L., Pezzilli R., Morselli-Labate A.M., Diabetes and the risk of pancreatic cancer, N. Engl. J. Med., 331, pp. 81-84, (1994)
  • [7] Permert J., Adrian T.E., Jacobsson P., Jorfelt L., Fruin A.B., Larsson J., Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?, Am. J. Surg., 165, pp. 61-67, (1993)
  • [8] Basso D., Valerio A., Seraglia R., Mazza S., Piva M.G., Greco E., Fogar P., Gallo N., Pedrazzoli S., Tiengo A., Plebani M., Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide, Pancreas, 24, pp. 8-14, (2002)
  • [9] Liu J., Knezetic J.A., Strommer L., Permert J., Larsson J., Adrian T.E., The intracellular mechanism of insulin resistance in pancreatic cancer patients, J. Clin. Endocrinol. Metab., 85, pp. 1232-1238, (2000)
  • [10] Isaksson B., Strommer L., Friess H., Buchler M.W., Herrington M.K., Wang F., Zierath J.R., Wallberg-Henriksson H., Larsson J., Permert J., Impaired insulin action on phosphatidylinositol 3-kinase and glucose transport in skeletal muscle of pancreatic cancer patients, Pancreas
1234567